Vanrafia
(Atrasentan)ApprovedSmall molecule
NovartisAtrasentan is used to treat a kidney disease called IgA nephropathy by reducing protein leakage into the urine. The medication works by blocking a substance in the body that causes kidney inflammation, helping to slow the progression of the disease.[2] Vanrafia is currently approved and in use across 3 indications[4].[1]
Vanrafia is one of 38 small molecule programs targeting IgA Nephropathy (IgAN). It is currently in Approved.
3
Indications
16
Total Trials
3
Active Trials
37
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
43 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Rituxan
RocheApproved
Lorelco
SanofiApproved
Fabhalta
NovartisApproved
Velcade
SShilpa Grover, MD, MPH
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Vanrafia
NovartisApproved
Filspari
TTravere Therapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer4 trials
Albuminuria2 trials
6 more indications
Coronary Artery Disease1 trial
Nephropathy1 trial
IgA Nephropathy (IgAN)1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Apr 2, 2025
VANRAFIA
NDA NDA219208
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Vanrafia drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Atrasentan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]